Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.75 CAD | -0.35% | +0.52% | +10.79% |
22/03 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
21/03 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company has insufficient levels of profitability.
- With an expected P/E ratio at 64.11 and 59.18 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.79% | 425M | D+ | ||
+12.55% | 9B | A- | ||
-12.75% | 4.96B | A- | ||
+42.38% | 4.47B | - | ||
+5.23% | 3.9B | B- | ||
+20.51% | 2.45B | B | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - | |
+4.58% | 1.65B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GUD Stock
- Ratings Knight Therapeutics Inc.